Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity

•KRAS mutations are the most common genetic event in lung adenocarcinoma.•The prognostic and predictive value of KRAS mutations is unclear.•Previous attempts to directly target KRAS have been unsuccessful.•A large number of novel agents and combinations are being currently evaluated.